Stay updated on Nivolumab for ALK+ ALCL: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.

Latest updates to the Nivolumab for ALK+ ALCL: Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to include a new version of the trial description for the treatment of relapsing/refractory ALK+ Anaplastic Large Cell Lymphoma, specifically detailing the trial's structure and cohorts. The principal investigator's name has also been added.SummaryDifference49%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Nivolumab for ALK+ ALCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for ALK+ ALCL: Clinical Trial page.